Prevalence of visceral leishmaniasis among people with HIV: a systematic review and meta-analysis

Abstract

Leishmaniasis is a parasitic infection expressing different clinical phenotypes. Visceral leishmaniasis (VL) is considered an opportunistic infection among people with human immunodeficiency virus (HIV). The objective of this review was to identify published data on the prevalence of Leishmania spp. infection among PWH and to define particular determinants that affect critically the epidemiological characteristics of VL-HIV coinfection and, potentially, its burden on public health. Two independent reviewers conducted a systematic literature search until June 30, 2022. Meta-analyses were conducted using random-effects models to calculate the summary prevalence and respective 95% confidence intervals (CI) of leishmaniasis among PWH. Meta-regression analysis was performed to investigate the impact of putative effect modifiers, such as the mean CD4 cell count, on the major findings. Thirty-four studies were eligible, yielding a summary prevalence of 6% (95%CI, 4–11%) for leishmaniasis (n = 1583) among PWH (n = 85,076). Higher prevalence rates were noted in Asia (17%, 95%CI, 9–30%) and America (9%, 95%CI, 5–17%) than in Europe (4%, 95%CI, 2–8%). Prevalence rates were significantly mediated by the age, sex, and CD4 cell count of participants. Heterogeneity remained significant in all meta-analyses (p < 0.0001). In the majority of included studies, people were coinfected with HIV and Leishmania species associated with VL, as opposed to those associated with cutaneous leishmaniasis. No sign of publication bias was shown (p = 0.06). Our summary of published studies on leishmaniasis among PWH is important to provide prevalence estimates and define potential underlying factors that could guide researchers to generate and further explore specific etiologic hypotheses.

Visceral leishmaniasis in Kosovo: A case of misdiagnosis and diagnostic challenges

“…A variety of infections coexist with leishmaniasis, such as HIV, leprosy, tuberculosis, schistosomiasis, Covid-19, etc., and the prevalence is different in different parts of the world. The impacts of coinfections are observed in immunopathogenesis, clinical manifestation, diagnosis, and therapeutic response [15] , [16] , [17] , [18] .…”

Visceral Leishmaniasis in Iran: An Update on Epidemiological Features from 2013 to 2022

“…Co-morbidities are one of the major contributing factors ( 62 , 67 ). Several studies have conclusively proven immunosuppression and malnutrition as risk factors for VL infection and the most significant is HIV ( 62 , 68 ). VL-HIV co-infection was initially identified in Spain ( 69 ) and had been reported in Iran ( 70 , 71 ).…”

Knock, knock, knocking on Europe’s door: Threat of leishmaniasis in Europe with a focus on Turkey

“…The disease is endemic in various regions, including mainland Greece and several islands ( Maia et al, 2023 ). The highest incidence rates are observed in the southern parts of the country, such as the Peloponnese, Crete, and the Ionian Islands ( Kantzanou et al, 2023 ). However, there have been reports of leishmaniasis cases in previously non-endemic areas of Greece, such as the northern regions of Thessaly and Epirus ( Symeonidou et al, 2021 ).…”

“…Co-infection with HIV poses a significant challenge for VL control, as it increases the risk of clinical disease and relapse, reduces treatment response, and facilitates the spread of the parasite. In the 1990s, HIV/VL coinfection played a crucial role in the re-emergence of VL in southern Europe, and it remains a public health concern, particularly in countries with high HIV prevalence, like Spain and Portugal ( Barth-Jaeggi and Mäser, 2021 ; Kantzanou et al, 2023 ).…”